1
|
Atkinson SJ, Bagal SK, Argyrou A, Askin S, Cheung T, Chiarparin E, Coen M, Collie IT, Dale IL, De Fusco C, Dillman K, Evans L, Feron LJ, Foster AJ, Grondine M, Kantae V, Lamont GM, Lamont S, Lynch JT, Nilsson Lill S, Robb GR, Saeh J, Schimpl M, Scott JS, Smith J, Srinivasan B, Tentarelli S, Vazquez-Chantada M, Wagner D, Walsh JJ, Watson D, Williamson B. Development of a Series of Pyrrolopyridone MAT2A Inhibitors. J Med Chem 2024. [PMID: 38466661 DOI: 10.1021/acs.jmedchem.3c01860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/13/2024]
Abstract
The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 (21), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors.
Collapse
Affiliation(s)
- Stephen J Atkinson
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Sharan K Bagal
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Argyrides Argyrou
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Sean Askin
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Tony Cheung
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Elisabetta Chiarparin
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Muireann Coen
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Iain T Collie
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Ian L Dale
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Claudia De Fusco
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Keith Dillman
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Laura Evans
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Lyman J Feron
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Alison J Foster
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Michael Grondine
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Vasudev Kantae
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Gillian M Lamont
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Scott Lamont
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - James T Lynch
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Sten Nilsson Lill
- Data Sciences & Modelling, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg 431 83, Sweden
| | - Graeme R Robb
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Jamal Saeh
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Marianne Schimpl
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - James S Scott
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - James Smith
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Bharath Srinivasan
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Sharon Tentarelli
- Oncology R&D, AstraZeneca, R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
| | - Mercedes Vazquez-Chantada
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - David Wagner
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Jarrod J Walsh
- Discovery Sciences R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - David Watson
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| | - Beth Williamson
- Oncology R&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K
| |
Collapse
|
2
|
Kettle JG, Bagal SK, Barratt D, Bodnarchuk MS, Boyd S, Braybrooke E, Breed J, Cassar DJ, Cosulich S, Davies M, Davies NL, Deng C, Eatherton A, Evans L, Feron LJ, Fillery S, Gleave ES, Goldberg FW, Cortés González MA, Guerot C, Haider A, Harlfinger S, Howells R, Jackson A, Johnström P, Kemmitt PD, Koers A, Kondrashov M, Lamont GM, Lamont S, Lewis HJ, Liu L, Mylrea M, Nash S, Niedbala MJ, Peter A, Phillips C, Pike K, Raubo P, Robb GR, Ross S, Sanders MG, Schou M, Simpson I, Steward O. Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS G12C with Demonstrable CNS Penetration. J Med Chem 2023. [PMID: 37395055 DOI: 10.1021/acs.jmedchem.3c00746] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
The glycine to cysteine mutation at codon 12 of Kirsten rat sarcoma (KRAS) represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of 14, AZD4747, a clinical development candidate for the treatment of KRASG12C-positive tumors, including the treatment of central nervous system (CNS) metastases. Building on our earlier discovery of C5-tethered quinazoline AZD4625, excision of a usually critical pyrimidine ring yielded a weak but brain-penetrant start point which was optimized for potency and DMPK. Key design principles and measured parameters that give high confidence in CNS exposure are discussed. During optimization, divergence between rodent and non-rodent species was observed in CNS exposure, with primate PET studies ultimately giving high confidence in the expected translation to patients. AZD4747 is a highly potent and selective inhibitor of KRASG12C with an anticipated low clearance and high oral bioavailability profile in humans.
Collapse
Affiliation(s)
| | | | - Derek Barratt
- Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K
| | | | - Scott Boyd
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Jason Breed
- Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K
| | | | | | | | | | - Chao Deng
- Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China
| | | | - Laura Evans
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | | | - Emma S Gleave
- Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K
| | | | - Miguel A Cortés González
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden
| | | | - Afreen Haider
- Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K
| | | | | | - Anne Jackson
- Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K
| | - Peter Johnström
- PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden
| | | | - Alex Koers
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Mikhail Kondrashov
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden
| | | | - Scott Lamont
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Libin Liu
- Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China
| | - Megan Mylrea
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Samuel Nash
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Alison Peter
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Kurt Pike
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Piotr Raubo
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Sarah Ross
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | - Magnus Schou
- PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden
| | - Iain Simpson
- Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | |
Collapse
|
3
|
Kawatkar A, Clark RA, Hopcroft L, Roaquin DA, Tomlinson R, Zuhl AM, Lamont GM, Kettle JG, Critchlow SE, Castaldi MP, Goldberg FW, Zhang AX. Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit. ACS Chem Biol 2023; 18:296-303. [PMID: 36602435 DOI: 10.1021/acschembio.2c00666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Lactic acid transport is a key process maintaining glycolytic flux in tumors. Inhibition of this process will result in glycolytic shutdown, impacting on cell growth and survival and thus has been pursued as a therapeutic approach for cancers. Using a cell-based screen in a MCT4-dependent cell line, we identified and optimized compounds for their ability to inhibit the efflux of intracellular lactic acid with good physical and pharmacokinetic properties. To deconvolute the mechanism of lactic acid efflux inhibition, we have developed three assays to measure cellular target engagement. Specifically, we synthesized a biologically active photoaffinity probe (IC50 < 10 nM), and using this probe, we demonstrated selective engagement of MCT4 of our parent molecule through a combination of confocal microscopy and in-cell chemoproteomics. As an orthogonal assay, the cellular thermal shift assay (CETSA) confirmed binding to MCT4 in the cellular system. Comparisons of lactic acid efflux potencies in cells with differential expression of MCT family members further confirmed that the optimized compounds inhibit the efflux of lactic acid through the inhibition of MCT4. Taken together, these data demonstrate the power of orthogonal chemical biology methods to determine cellular target engagement, particularly for proteins not readily amenable to traditional biophysical methods.
Collapse
Affiliation(s)
- Aarti Kawatkar
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| | - Roger A Clark
- Discovery Sciences, R&D, AstraZeneca, CambridgeCB2 0AA, U.K
| | | | - Debora Ann Roaquin
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| | - Ronald Tomlinson
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| | - Andrea M Zuhl
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| | | | | | | | - M Paola Castaldi
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| | | | - Andrew X Zhang
- Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States
| |
Collapse
|
4
|
Goldberg FW, Kettle JG, Lamont GM, Buttar D, Ting AKT, McGuire TM, Cook CR, Beattie D, Morentin Gutierrez P, Kavanagh SL, Komen JC, Kawatkar A, Clark R, Hopcroft L, Hughes G, Critchlow SE. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. J Med Chem 2023; 66:384-397. [PMID: 36525250 DOI: 10.1021/acs.jmedchem.2c01342] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Due to increased reliance on glycolysis, which produces lactate, monocarboxylate transporters (MCTs) are often upregulated in cancer. MCT4 is associated with the export of lactic acid from cancer cells under hypoxia, so inhibition of MCT4 may lead to cytotoxic levels of intracellular lactate. In addition, tumor-derived lactate is known to be immunosuppressive, so MCT4 inhibition may be of interest for immuno-oncology. At the outset, no potent and selective MCT4 inhibitors had been reported, but a screen identified a triazolopyrimidine hit, with no close structural analogues. Minor modifications to the triazolopyrimidine were made, alongside design of a constrained linker and broad SAR exploration of the biaryl tail to improve potency, physical properties, PK, and hERG. The resulting clinical candidate 15 (AZD0095) has excellent potency (1.3 nM), MCT1 selectivity (>1000×), secondary pharmacology, clean mechanism of action, suitable properties for oral administration in the clinic, and good preclinical efficacy in combination with cediranib.
Collapse
Affiliation(s)
| | | | | | - David Buttar
- Pharmaceutical Sciences, AstraZeneca, Macclesfield SK10 2NA, U.K
| | | | | | - Calum R Cook
- Pharmaceutical Sciences, AstraZeneca, Macclesfield SK10 2NA, U.K
| | | | | | - Stefan L Kavanagh
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K
| | - Jasper C Komen
- Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K
| | - Aarti Kawatkar
- Discovery Sciences, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Roger Clark
- Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K
| | | | | | | |
Collapse
|
5
|
Goldberg FW, Ting AKT, Beattie D, Lamont GM, Fallan C, Finlay MRV, Williamson B, Schimpl M, Harmer AR, Adeyemi OB, Nordell P, Cronin AS, Vazquez-Chantada M, Barratt D, Ramos-Montoya A, Cadogan EB, Davies BR. Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8 H-purin-8-one Inhibitors of DNA-PK. ACS Med Chem Lett 2022; 13:1295-1301. [PMID: 35978693 PMCID: PMC9377022 DOI: 10.1021/acsmedchemlett.2c00172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The DNA-PK complex is activated by double-strand DNA breaks and regulates the non-homologous end-joining repair pathway; thus, targeting DNA-PK by inhibiting the DNA-PK catalytic subunit (DNA-PKcs) is potentially a useful therapeutic approach for oncology. A previously reported series of neutral DNA-PKcs inhibitors were modified to incorporate a basic group, with the rationale that increasing the volume of distribution while maintaining good metabolic stability should increase the half-life. However, adding a basic group introduced hERG activity, and basic compounds with modest hERG activity (IC50 = 10-15 μM) prolonged QTc (time from the start of the Q wave to the end of the T wave, corrected by heart rate) in an anaesthetized guinea pig cardiovascular model. Further optimization was necessary, including modulation of pK a, to identify compound 18, which combines low hERG activity (IC50 = 75 μM) with excellent kinome selectivity and favorable pharmacokinetic properties.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Alexander R. Harmer
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
| | - Oladipupo B. Adeyemi
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
| | - Pär Nordell
- Biopharmaceuticals
R&D, AstraZeneca, 431 50 Gothenburg, Sweden
| | - Anna S. Cronin
- Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
| | | | - Derek Barratt
- Discovery
Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
| | | | | | | |
Collapse
|
6
|
Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, Wrigley GL, Schimpl M, Howard MR, Williamson B, Vazquez-Chantada M, Barratt DG, Davies BR, Cadogan EB, Ramos-Montoya A, Dean E. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- a]pyridin-6-yl)amino]-9-(tetrahydro-2 H-pyran-4-yl)-7,9-dihydro-8 H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J Med Chem 2020; 63:3461-3471. [PMID: 31851518 DOI: 10.1021/acs.jmedchem.9b01684] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
DNA-PK is a key component within the DNA damage response, as it is responsible for recognizing and repairing double-strand DNA breaks (DSBs) via non-homologous end joining. Historically it has been challenging to identify inhibitors of the DNA-PK catalytic subunit (DNA-PKcs) with good selectivity versus the structurally related PI3 (lipid) and PI3K-related protein kinases. We screened our corporate collection for DNA-PKcs inhibitors with good PI3 kinase selectivity, identifying compound 1. Optimization focused on further improving selectivity while improving physical and pharmacokinetic properties, notably co-optimization of permeability and metabolic stability, to identify compound 16 (AZD7648). Compound 16 had no significant off-target activity in the protein kinome and only weak activity versus PI3Kα/γ lipid kinases. Monotherapy activity in murine xenograft models was observed, and regressions were observed when combined with inducers of DSBs (doxorubicin or irradiation) or PARP inhibition (olaparib). These data support progression into clinical studies (NCT03907969).
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Derek G Barratt
- Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0FZ, U.K
| | | | | | | | - Emma Dean
- Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K
| |
Collapse
|
7
|
McCoull W, Hennessy EJ, Blades K, Box MR, Chuaqui C, Dowling JE, Davies CD, Ferguson AD, Goldberg FW, Howe NJ, Kemmitt PD, Lamont GM, Madden K, McWhirter C, Varnes JG, Ward RA, Williams JD, Yang B. Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity. Med Chem Commun 2014. [DOI: 10.1039/c4md00280f] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
8
|
Kemmitt PD, Blades K, Box MR, Dickinson S, Lamont GM, Madden K, McCoull W, Williams J. Synthesis of 3-(Hetero)aryl Tetrahydropyrazolo[3,4-c]pyridines by Suzuki–Miyaura Cross-Coupling Methodology. J Org Chem 2014; 79:7682-8. [DOI: 10.1021/jo5012015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Paul D. Kemmitt
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Kevin Blades
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Matthew R. Box
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Stephanie Dickinson
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Gillian M. Lamont
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Katrina Madden
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - William McCoull
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| | - Jason Williams
- AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom
| |
Collapse
|
9
|
Bethel PA, Campbell AD, Goldberg FW, Kemmitt PD, Lamont GM, Suleman A. Optimized scale up of 3-pyrimidinylpyrazolo[1,5-a]pyridine via Suzuki coupling; a general method of accessing a range of 3-(hetero)arylpyrazolo[1,5-a]pyridines. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.04.094] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Finlay MRV, Buttar D, Critchlow SE, Dishington AP, Fillery SM, Fisher E, Glossop SC, Graham MA, Johnson T, Lamont GM, Mutton S, Perkins P, Pike KG, Slater. AM. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. Bioorg Med Chem Lett 2012; 22:4163-8. [DOI: 10.1016/j.bmcl.2012.04.036] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Revised: 04/05/2012] [Accepted: 04/08/2012] [Indexed: 10/28/2022]
|
11
|
Luke RW, Addie M, Box MR, Buttar D, Crafter C, Currie GS, Cosulich SC, Davies B, Dudley PG, Greenwood R, Johnson PD, Greenwood H, Lamont GM, Lane C, Page KM, Pearson SE, Ruston L. Abstract 4478: Discovery of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT kinases. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
AKT is a key node in the most frequently de-regulated signaling pathway in human cancer and has been shown to mediate resistance to a range of cytotoxic, anti-hormonal and targeted therapies. We decided to explore inhibitors of AKT as potential new anti-cancer therapeutics. Here we disclose for the first time the discovery and structure of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT. We evaluated a range of chemical starting points arising from our previous collaboration with the Institute of Cancer Research and Astex Therapeutics Ltd. Ultimately AZD5363 was discovered following a long journey that started from a pyrrolopyrimidine series of compounds. Our first challenge was to improve potency and a second challenge was to improve ROCK selectivity. ROCK is an AGC kinase like AKT but is involved in regulation of vascular tone and thus blood pressure. Extensive SAR studies exploring the series revealed that achieving selectivity over ROCK while retaining AKT potency was quite challenging. Eventually we discovered ways which could improve both selectivity and potency. However, these compounds had significant activity against the hERG ion channel which is implicated in the development of Torsades de Pointes and cardiac death. The next phase of work therefore had to focus on reducing hERG activity, while at the same time not adversely impacting either AKT potency or ROCK selectivity. Finally we discovered that introduction of a key substituent group provided a compound that achieved reduced hERG potency and, surprisingly, also achieved a further small improvement in both AKT potency and ROCK selectivity. This compound was AZD5363. A crystal structure of AZD5363 bound to AKT has revealed some of the key interactions that may contribute to its potency. For example, the pyrrolopyrimidine appears to form hydrogen bonds to the hinge region of the kinase. AZD5363 inhibits all known AKT isoforms with a potency of <10 nM and inhibits phosphorylation of the AKT substrate, PRAS40 in BT474c cells with a potency of 0.31 μM. Activity in in vivo pharmacodynamic and xenograft models has also been demonstrated. A synthetic route suitable for scale-up has been developed. In conclusion, AZD5363 is a potent inhibitor of AKT in vitro and in cells. It has good hERG and ROCK selectivity. It has pharmacodynamic and xenograft activity in vivo. AZD5363 has potential in cancer therapy and is currently in phase 1 clinical trials.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4478. doi:10.1158/1538-7445.AM2011-4478
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Clare Lane
- 1AstraZeneca, Macclesfield, United Kingdom
| | | | | | | |
Collapse
|
12
|
Read HS, Wyatt JP, Lamont GM, Scobie WG. Pyloric stenosis in preterm twins. J R Coll Surg Edinb 1994; 39:187-8. [PMID: 7932343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- H S Read
- Department of Paediatric Surgery, Royal Hospital for Sick Children, Edinburgh, UK
| | | | | | | |
Collapse
|
13
|
Abstract
The fat component of meals has been thought to make a major contribution to the colonic response to feeding. We have combined gamma scintigraphy and radiotelemetry to noninvasively study the response of the normally inaccessible proximal colon after ingestion of either a high or low fat meal. Separate studies were performed to measure the rate of passage of the same meals through the whole gut. Gastric emptying and small bowel transit of the two meals to the colon was similar, 50% of meal marker reaching the ascending colon 4.8 +/- 0.2 and 4.5 +/- 0.3 hr after the high and low fat meals respectively (N = 8, difference not significant). The low fat meal caused a consistent increase in motility index, which rose from a basal value of 1.0 +/- 0.3 to 2.6 +/- 0.7 mm Hg in the 2 hr after the meal (N = 8, P < 0.01). Response to the high fat meal was less consistent, motility index increasing from 1.6 +/- 0.6 basally to 2.3 +/- 0.7 mm Hg postprandially (N = 8, P = 0.21). Despite these increases in motor activity there was no net caudal propulsion of colonic contents after either meal. The geometric center was comparable, being 3.2 +/- 0.4 and 3.7 +/- 0.4 before the high and low fat meals. This did not change significantly after either meal, being then 3.5 +/- 0.4 and 3.6 +/- 0.4 2 hr after the high and low fat meals, respectively. We conclude that in normal subjects equicaloric high and low fat meals transit the whole gut at a similar rate.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K P Steed
- Department of Physiology, University Hospital Medical School, Queen's Medical Center, Nottingham, UK
| | | | | | | | | | | |
Collapse
|